Nasdaq:US$13.89 (+0.03) | HKEX:HK$22.45 (+0.50) | AIM:£2.07 (+0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors